Teva Pharmaceutical Industries Limited ( NYSE: TEVA) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Richard D. Francis - President, CEO & Director ...

Patent lawyers are racing to adapt how they draft and defend drug-device patents after a court ruling reshaped the FDA’s ...

Teva Pharmaceuticals has been recognized with the 2025 Power of Partnership Award by Americares, in collaboration with the Healthcare Distribution Alliance (HDA), for its exceptional commitment to ...

Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Teva Pharmaceutical Industries Limited - Depositary ...

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its ...

Chicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved ...

Teva Pharmaceutical Industries (TEVA) announced the pricing and early acceptance results of its previously announced tender offers to buy for cash the outstanding notes.

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

Teva got more time to ask the Supreme Court to review a ruling that could strip hundreds of drug patents from a key FDA registry, a decision the company says could reshape how makers of brand-name ...